Literature DB >> 8481078

Fluconazole-resistant Candida albicans after long-term suppressive therapy.

A Sanguineti1, J K Carmichael, K Campbell.   

Abstract

Candida albicans is generally considered to be susceptible, in vivo, to fluconazole. In the population infected with human immunodeficiency virus, recurrent bouts of oral and esophageal candidiasis have led to increasing use of fluconazole for long-term prophylaxis. With prolonged therapy, the issue of developing resistance emerges. We report a case of fluconazole-resistant C albicans esophagitis that developed after fluconazole was used for more than 600 days.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481078

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  22 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  S Vora; N Purimetla; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

Authors:  F Barchiesi; L Falconi Di Francesco; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 7.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

8.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

9.  Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.

Authors:  F Dronda; M Alonso-Sanz; F Laguna; F Chaves; J V Martínez-Suárez; J L Rodríguez-Tudela; A González-López; E Valencia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.